The Gross Law Firm has issued a shareholder alert for GRAIL, Inc., setting an August 4, 2026 deadline for investors to seek lead plaintiff appointment in a securities class action. The class period runs from May 13, 2025 to February 19, 2026, covering allegations that the company made false and misleading statements about its NHS-Galleri trial. On February 19, 2026, GRAIL announced the trial's primary endpoint of a statistically significant reduction in Stage III-IV cancers was not observed, causing its stock to plummet from $101.53 to $50.21 per share in a single day, a decline of about 50.55%. Shareholders who purchased GRAL shares during the class period are encouraged to register for the action, with no cost or obligation to participate.
GRAIL, LLCSecurities class action alleging false statements about NHS-Galleri trial; stock fell 50.55% on trial failure announcement.